Prostate organoids model benign prostatic hyperplasia and prostate cancer. Patient-derived models enable personalized treatment selection for castration-resistant prostate cancer and androgen receptor-targeted therapies.
CRPC
Castration-Resistant
Model advanced prostate cancer resistant to hormone therapy.
AR-TARGETING
Drug Response
Screen novel androgen receptor antagonists and degraders.